1. Scrip
  2. >>Focus On Asia
  3. >>China

China’s First Biotech Refinancing Deals in 2022 To Raise $712m

 
• By Dexter Jie Yan

Junshi and Chipscreen expect to raise a combined $711.9m in a private stock placement and issuance of convertible bonds to fund facilities construction and R&D.

fund raising
deals are first such attempt by Chinese biotechs to raise post-STAR Market IPO funds • Source: Alamy

Two domestically-listed Chinese biotechs are looking to strike refinancing deals to raise a combined $711.9m on the country’s Nasdaq-equivalent STAR Market under the Shanghai Stock Exchange.

Hong Kong- and Shanghai-listed Shanghai Junshi Biosciences Co., Ltd. on 7 March announced it plans to raise roughly CNY4.0bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

More from Focus On Asia